İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2017

Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population

Ovid Technologies (Wolters Kluwer Health)

YÖKSİS OpenAlex SJR Q2 JCR Q4 Atıf 18 Yüzdelik 69.8% FWCI 0.65
Yıl
2017
ISSN
1077-4114
Tür
article

Veri kaynağı ayrımı

  • YÖKSİS YÖKSİS makale kaydı
  • OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

İngilizce (OpenAlex)

Vincristine is a widely used chemotherapeutic agent in the treatment of childhood malignancies. Neuropathy is the most common adverse effect. CYP3A4 and CYP3A5 enzymes of cytochrome p450 enzyme system are responsible in vincristine metabolism. Genetic polymorphism may alter the vincristine metabolism and the neurotoxicity rate. In this study, distribution of CYP3A5 alleles among Turkish children with malignancies, relation between CYP3A5 genotype and neurotoxicity rates, as well as severity and duration of neuropathy and total vincristine doses were investigated. Patient group consisted of 115 patients (age, 1 to 17 y) with acute lymphoblastic leukemia and solid tumors, who were treated with vincristine consisting chemotherapy protocols. Control group consisted of 50 children without any neurological symptom or disorders. All patient files were reviewed for presence and severeness of neurotoxicity symptoms. Blood samples were obtained and CYP3A5 genotypes were analyzed. Neurotoxicity occurred in 20.8% of patients. Although it was found to occur more frequently after 4 doses of vincristine, and rates were higher in the low-dose vincristine group suggesting other contributing factors. Although neurotoxicity rate in the CYP3A5*1/*3 genotype was 17.6%, it was 21.6% in the CYP3A5*3/*3 genotype and the difference was not statistically significant (P<0.05). This study suggested that vincristine-related neurotoxicity is dose-independent and genotype is not the only causative factor in the occurrence of neurotoxicity in these patients.

Konular

  • Cancer Treatment and Pharmacology
  • Pharmacogenetics and Drug Metabolism
  • Cancer therapeutics and mechanisms

Birincil konu Cancer Treatment and Pharmacology

Yazarlar

  1. Hülya Kayılıoğlu
  2. ÜLKER KOÇAK
  3. Derya Kan Karaer
  4. FERDA EMRİYE PERÇİN
  5. Ertan Sal
  6. Funda Tekkesin
  7. Melek Işık
  8. Nergis Öner
  9. FATMA BURCU BELEN APAK
  10. Ebru Keskin Yılmaz
  11. ARZU OKUR GAZİ ÜNİVERSİTESİ
  12. Meryem Albayrak
  13. ZÜHRE KAYA
  14. FARUK GÜÇLÜ PINARLI GAZİ ÜNİVERSİTESİ
  15. İDİL YENİCESU
  16. CEYDA KARADENİZ
  17. Aynur Oğuz
  18. Türkiz Gürsel